Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Lumexa Imaging Holdings, Inc. (LMRI) SEC Filings & Earnings Calls

EquiReason read 9 Lumexa Imaging Holdings, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-13 — Q2 2026 net sales grew 24.1% YoY but gross margin contracted sharply to 19.5% from 28.6%, net income fell to $0.1M from $4.2M..

Source: SEC EDGAR filings · read by EquiReason

LMRILumexa Imaging Holdings, Inc.Follow LMRI — free
Diagnostics & Research · Healthcare
—
Price chart with a free account
Market cap
1.1B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
12 Nov, in 19 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

13 Aug 202610-QQ2 2026 net sales grew 24.1% YoY but gross margin contracted sharply to 19.5% from 28.6%, net income fell to $0.1M from $4.2M.earningsopen

Figures in the filing · each found in the filing text

Net sales · Q2-2026$67M+24% y/y
Gross profit margin · Q2-202619.5%
Net income · Q2-2026$127000.00-97% y/y
Selling expenses as % of net sales · Q2-202611.4%
Drinkable Kefir net sales · Q2-2026$59M+27% y/y
Capital expenditures · H1-2026$20M+331% y/y
Line of credit outstanding · 2026-06-30$22M
Advertising expense · Q2-2026$5M+110% y/y

Risks flagged

Input cost inflation

“The decrease versus the prior year was driven by the unfavorable impact of milk pricing and to a lesser extent the unfavorable impact of resin-based packaging inputs and transportation costs.”

Customer concentration

“Two major customers accounted for a total of 25% of net sales for the six months ended June 30, 2026 and 2025.”
Read the original on SEC EDGAR ↗
12 Aug 20268-K · 2.02, 7.01Lumexa Imaging reported Q2 2026 results with revenue growth of 5.1% to $264.2M, net income improvement to $2.7M from a loss, and narrowed FY2026 Adjusted EBITDA guidance range. Same-center advanced volume grew 5.2%.earningsopen

Figures in the filing · each found in the filing text

Consolidated revenues · Q2-2026$264M+5% y/y
Net income · Q2-2026$3M-138% y/y
Adjusted EBITDA · Q2-2026$56M+0% y/y
Adjusted EBITDA margin · Q2-202621.4%
GAAP EPS · Q2-2026$0.03
Adjusted EPS · Q2-2026$0.20
Consolidated total procedures · Q2-2026617,722+3% y/y
Consolidated advanced procedures · Q2-2026193,125+7% y/y
System-wide revenue growth · Q2-20266.0%

Guidance

FY26 revenue reiterated $1.045B-$1.097B; FY26 Adjusted EBITDA narrowed to $235M-$241M from $234M-$242M (midpoint unchanged at $238M); FY26 Adjusted EPS reiterated $0.71-$0.77

Revenue and EPS guidance reaffirmed; EBITDA guidance range narrowed with unchanged midpoint; margin pressure from public company costs

Risks flagged

Adjusted EBITDA margin compression due to public company costs

“Adjusted EBITDA margin declined from 22.4% to 21.4%; includes approximately $7 million of public company costs not incurred in 2025”
Read the original on SEC EDGAR ↗
30 Jun 20268-K · 1.01, 2.03Lumexa Imaging enters amendment to credit agreement: $823M secured term loan (SOFR+2.50%) due Dec 2032 and $250M revolver (SOFR+2.50%) due Dec 2030; net leverage covenant ≤7.5x if triggered.open

Figures in the filing · each found in the filing text

Term loan amount · June 30, 2026$823M
Revolving credit facility · June 30, 2026$250M
Interest rate (term loan) · June 30, 20262.5%

Risks flagged

High leverage with net leverage covenant at 7.5x; potential constraint if revolver drawn.

“Consolidated net leverage ratio shall not exceed 7.50 to 1 if covenant triggered.”

Substantial debt secured by substantially all assets; default risk if covenants breached.

“Secured by substantially all of their assets; various customary remedies for Lenders following an event of default.” · word for word
Read the original on SEC EDGAR ↗
12 May 20268-K · 2.02, 7.01Q1 2026 revenue $252.5M (+3.1% YoY), net income $1.7M vs loss $7.7M, adjusted EBITDA $51.2M, same-center advanced volume growth 5.6%, reiterated FY2026 guidance.earningsopen

Figures in the filing · each found in the filing text

Consolidated revenues · Q1-2026$253M+3% y/y
Net income · Q1-2026$2M-122% y/y
Adjusted EBITDA · Q1-2026$51M+0% y/y
GAAP EPS · Q1-2026$0.02
Adjusted EPS · Q1-2026$0.18
Consolidated total procedures · Consolidated · Q1-2026586,337+1% y/y
Consolidated advanced procedures · Consolidated · Q1-2026182,176+7% y/y
Same-center advanced volume growth · Consolidated · Q1-20265.6%

Guidance

FY26 consolidated revenues $1.045-1.097B; FY26 adjusted EBITDA $234-242M (includes ~$7M public company costs); FY26 adjusted EPS $0.71-0.77

Reiterated full year 2026 guidance across all metrics.

Risks flagged

Public company costs impacting adjusted EBITDA growth by ~3%.

“approximately $7 million of public company costs that were not incurred in 2025” · word for word
Read the original on SEC EDGAR ↗
12 May 202610-QCompany reported net income of $1.7 million for Q1 2026, improving from a net loss of $7.7 million in Q1 2025, driven by lower interest expense, though operating income declined 24% due to margin compression.earningsopen

Figures in the filing · each found in the filing text

Consolidated net patient service revenue · Q1-2026$197M+3% y/y
Total revenues · Q1-2026$253M+3% y/y
Income from operations · Q1-2026$19M-24% y/y
Net income (loss) · Q1-2026$2M
Centers in operation · 2026-03-31189+4% y/y
Equity in earnings of unconsolidated affiliates · Q1-2026$15M-2% y/y

Risks flagged

Operating margin compression

“Cost of operations as % of revenue increased from 85.1% to 86.2%.”

Seasonality risk

“The first quarter of each year generally sees the lowest procedure volumes and revenue levels.” · word for word

Reimbursement risk

“If we are not able to obtain or maintain coverage and adequate reimbursement from commercial payors, we may not be able to effectively increase our patient volume and revenue as expected.” · word for word
Read the original on SEC EDGAR ↗
28 Apr 2026DEF 14ADEF 14A proxy statement filed for 2026 annual meeting; discloses executive compensation, director compensation, ownership, and governance structure post-IPO.open

Risks flagged

Key person dependency on CEO and CFO

“CEO and CFO both appointed in January 2025; large signing bonuses and equity grants indicate retention risk.”

Concentrated ownership and control by WCAS

“WCAS holds 73.1% of shares and has board designation rights, giving it significant control.”
Read the original on SEC EDGAR ↗
30 Mar 202610-KAnnual report shows strong revenue growth (+7.8% to $1.023B), robust Adjusted EBITDA margin (22.5%), and positive same-center volume growth, despite net loss of $47.1M.earningsopen

Figures in the filing · each found in the filing text

Consolidated Revenue · FY2025$1.02B+8% y/y
Adjusted EBITDA · FY2025$230M
Net Loss · FY2025$47M
Number of Centers · FY2025188
Same-Center CT Volume Growth · Consolidated · FY20257.5%
Same-Center MRI Volume Growth · Consolidated · FY20258.3%
Number of Referring Physicians · FY2025102,000
Patient Net Promoter Score · FY202591
Patient Satisfaction Rate · FY202597.0%
Referring Physician Satisfaction Rate · FY202488.0%

Risks flagged

Reimbursement Rate Reduction Risk

“If reimbursement rates paid by third-party governmental or commercial payors are reduced or if we fail to successfully manage the reimbursement and collections processes, our business, financial condition, results of operations, liquidity and stock price could be harmed” · word for word

Radiologist Labor Shortage Risk

“We are dependent on our and our contracted radiology practices' ability to hire and retain qualified radiologists and radiologic technologists, as well as our ability to hire and retain key personnel” · word for word

Regulatory Compliance Risk

“The regulatory framework in which we operate is uncertain and continually evolving and complying with federal and state regulations is an expensive and time-consuming process” · word for word

Referral Dependency Risk

“Our ability to generate revenue depends in large part on referrals from physicians and other healthcare providers” · word for word

Fixed Cost / Volume Sensitivity Risk

“Because many of our costs are fixed, lower scan volumes or other decreases to revenues could adversely affect the profitability of our business” · word for word
Read the original on SEC EDGAR ↗
26 Mar 20268-K · 2.02, 7.01Lumexa Imaging reports Q4/FY2025 preliminary results: revenue $267.7M (+7.9%), Adj EBITDA $63.8M (+18.6%), leverage reduced 2 turns; reiterates FY2026 guidance: revenue $1.045-1.097B, Adj EBITDA $234-242M, Adj EPS $0.71-0.77.earningsopen

Figures in the filing · each found in the filing text

Consolidated revenue · Q4-2025$268M+8% y/y
Adjusted EBITDA · Q4-2025$64M+19% y/y
Adjusted EBITDA margin · Q4-202523.8%
Consolidated total procedures · Q4-2025627,293+10% y/y
Consolidated advanced procedures · Q4-2025190,982+14% y/y
Consolidated same-center advanced volume growth · Q4-202512.7%
Net loss · Q4-2025$-29M+14% y/y
Cash and cash equivalents · FY2025$59M+125% y/y

Guidance

FY2026 revenue $1.045-1.097B; Adj EBITDA $234-242M; Adj EPS $0.71-0.77

Reiterated FY2026 guidance with revenue growth and margin expansion; management cites durable demand tailwinds.

Risks flagged

Preliminary results subject to adjustment; net loss persists though improving.

“Preliminary, unaudited estimates subject to change; net loss $28.7M in Q4 vs $25.1M prior year.”

Guidance includes $7M of public company costs not incurred in 2025, pressuring Adj EBITDA growth.

“Adjusted EBITDA guidance includes approximately $7 million of public company costs that were not incurred in 2025.”
Read the original on SEC EDGAR ↗
2 Mar 20268-K · 2.02, 7.01Lumexa Imaging reports preliminary Q4/FY2025 results: Q4 revenue at least $261M (+5.2% YoY), FY revenue at least $1.016B (+7.1% YoY). Adjusted EBITDA Q4 at least $63M (+16.5% YoY), FY at least $229M (+14% YoY). Provides FY2026 guidance: revearningsopen

Figures in the filing · each found in the filing text

Consolidated Revenue · Q4-2025$261M+5% y/y
Consolidated Revenue · FY2025$1.02B+7% y/y
Adjusted EBITDA · Q4-2025$63M+17% y/y
Adjusted EBITDA · FY2025$229M+14% y/y
Net Loss · Q4-2025$-25M+1% y/y
Net Loss · FY2025$-44M-53% y/y
Consolidated Total Procedures · Q4-2025627,293+10% y/y
Consolidated Total Procedures · FY20252,418,096+5% y/y
Consolidated Advanced Procedures · Advanced (MRI, CT) · Q4-2025190,982+14% y/y
Consolidated Advanced Procedures · Advanced (MRI, CT) · FY2025728,304+8% y/y

Guidance

FY2026 consolidated revenue $1.045-1.097B; Adjusted EBITDA $234-242M (incl. ~$7M public company costs)

FY2026 guidance implies continued revenue growth of 3-8% and Adj. EBITDA growth of 2-6% (after public company costs). Management cites strong demand, de novo performance, and payer network expansion.

Risks flagged

Preliminary results subject to audit adjustment; final numbers may differ materially.

“The financial results included in this release pertaining to the fourth quarter and full year 2025 are preliminary, unaudited, and subject to final review and adjustment.” · word for word

Public company costs of ~$7M in 2026 will reduce Adj. EBITDA growth from 7% to 4% at midpoint.

“Adjusted EBITDA of $234 to $242 million, which includes approximately $7 million of public company costs that were not incurred in 2025. At the midpoint, the addition of these costs... lowers Adjusted EBITDA growth for 2026 versus 2025 from 7% to 4%.” · word for word
Read the original on SEC EDGAR ↗

Lumexa Imaging Holdings, Inc. — questions

What did Lumexa Imaging Holdings, Inc. file recently?
9 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-13 — Q2 2026 net sales grew 24.1% YoY but gross margin contracted sharply to 19.5% from 28.6%, net income fell to $0.1M from $4.2M.

Every figure on this page comes from Lumexa Imaging Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.